Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi all. I've been getting asked whether I know anything about when the company will emerge from the greys. The only info I've seen is dated April 17th.
April 17, 2020 -TheNewswire -VANCOUVER, British Columbia - Roadman Investments Corp. (TSXV:LITT)(FWB:1QD)(OTC:RMANF) ("Roadman Investments" or the "Company") announces that after trading hours on April 10, 2020 the Securities and Exchange Commission ("SEC") issued an Order (the "Order") in the public interest and protection of investors requiring a suspension in the trading of securities of Roadman Investments Corp. pursuant to Section 12(k) of the Securities Exchange Act of 1934. Under such Order trading in the securities of the Company in the United States is suspended for the period from 9:30 a.m. EDT, on April 13, 2020 through 11:59 p.m. EDT on April 24, 2020. The Order cites: "The Commission temporarily suspended trading in the securities of RMANF because of questions regarding the accuracy and adequacy of information in the marketplace disseminated by RMANF in at least twelve news releases since February 12, 2020. Those questions relate to statements RMANF made about its commercialization of cedar leaf oil as a promising treatment for COVID-19."
The Company has contacted the SEC to request details relating to their questions that formed the basis of the suspension but has not received any specific information from the SEC. The Company is eager to address any concerns the SEC has with its disclosures. The Company recently clarified some of its prior disclosures in its press release dated March 30, 2020 (filed March 31, 2020 on SEDAR) and encourages investors to read these clarifications.
The Company is communicating with the TSX Venture Exchange regarding the implications of the SEC order. The Company is a reporting issuer in British Columbia and Alberta. Neither the British Columbia Securities Commission nor the Alberta Securities Commission have issued a cease trade order against the Company's securities following the Order. However, the Company's shares will likely remain halted in Canada pending clarification of the SEC's concerns regarding the Company's disclosure.
Under Section 12(k) of the Act, the Commission is authorized to suspend trading in any security for a period not exceeding 10 business days if, in its opinion, is necessary to protect the public interest and investors. Following the suspension, limited or "unsolicited" trading can occur when a broker or adviser has not solicited or recommended such a transaction but broker-dealers will need to comply with Rule 15c2-11 prior to entering quotations relating to RMANF's securities.
https://www.otcmarkets.com/stock/RMANF/news/story?e&id=1578710
LOL... All jokes aside, my comments about them owning 1million SHRM shares and 750,000 warrants is not from a press release I read. It's in their SEDAR financial statements. They originally owned 1.5 million shares but sold 500,000 (unfortunately). I cannot copy the link to the specific SEDAR report so I will just tell you how to access it.
Go to the SEDAR website (see link): https://www.sedar.com/search/search_en.htm
Then click the box"Search for Company Documents" in the middle of the page
Then on the following page type "Roadman Investments Corp"
Then on the following page you will see a column titled "Document Type". Scroll down that column till you see one labeled "MD&A-English" from March 2,2020 and click the link to that.
Read page 2 of the document about Champagion Brands.
They should’ve known better to say anything non-FDA approved (like an oil) is a treatment for a disease.
did they open a trip center in cali or was that just pump talk?
i wonder how yhe snake oil sales are going?
RMANF NOW SHOWN ON GREY MARKET.
https://www.otcmarkets.com/stock/RMANF/overview
Well this is annoying. However, they still hold 1,000,000 shares of SHRM and 750,000 warrants of SHRM exercisable at $0.15/share. That is what makes them a “shroom company”.....They should’ve known better to say anything non-FDA approved (like an oil) is a treatment for a disease.
RMANF SEC Suspension "because of questions regarding the accuracy and adequacy of information in the marketplace disseminated by RMANF in at least twelve news releases since February 12, 2020. Those questions relate to statements RMANF made about its commercialization of cedar leaf oil as a promising treatment for COVID-19."
https://www.sec.gov/litigation/suspensions/2020/34-88619.pdf
Order:
https://www.sec.gov/litigation/suspensions/2020/34-88619-o.pdf
What is our next play????????
These are the early Dayz of the Shroom Revolution; Volume Will Increase as More Become Aware! And When It Does...
Volume: 3,000 @04/07/20 10:27:55 AM
RMANF owns 1,000,000 shares of SHRM and 750,000 SHRM warrants (exercisable at $0.15 per share that expire 8/15/2022).
Roadman Investments Corp RMANF
O/S 127,855,024 3/25/20
A$K thinning; .05's on deck!
She's Gonna Fly Peeps; Get Ready 4 BLAST-OFF!!!
RMANF SECURITY DETAILS
Market Cap Market Cap 2,659,384 03/30/2020
Authorized Shares Unlimited 04/29/2019
Outstanding Shares 127,217,524 03/30/2020
Restricted Not Available
Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Short Selling Data
Short Interest 186 (-92.83%) 03/13/2020
Pink Current Information
Roadman has been on an absolute tear signing new partnerships and strategic investing into the Shroom market!
March 31, 2020 - TheNewswire -VANCOUVER, British Columbia - Roadman
Investments Corp. (TSXV:LITT) (FWB:1QD) (OTC:RMANF)("Roadman Investments" or the "Company") is pleased to announce the signing of a definitive agreement with Psychedelic Insights to form a joint venture for the purpose of opening up a legal psychedelic treatment center in the state of California upon the legalization or medical approval of psilocybin.
Psychedelic Insights is one of the only companies in the world that offers psychological guided psychedelic experiences with magic psilocybin truffles in their safe psychedelic space in the center of Amsterdam. The company has experienced specialists, a passion for healing people, proven results, mature IT marketing and sales infrastructure with bookings system, CRM, Mail-systems, Screening evaluation, etc. Psychedelic Insights is perfect partner for Roadman as their business is very scalable across jurisdictions.
With the liberalisation of drug policies globally we anticipate the need for qualified certified therapists and practitioners to be a major bottleneck to growth. Psychedelic Insights offers a comprehensive training program that will allow the scale across the US as new states approve treatments. Roadman Investments providing capital and Psychedelic Insights providing the expertise and operating the centers. The number of researchers, universities, and other institutions conducting and publishing scientific studies on the healing powers of psychedelics is increasing daily and is at an all-time high. Stigma is dissolving and people are starting to seek out psychedelic experiences and we expect there to be a lot of demand for these mental health services in the future.
California is a great starting point for the first Psychedelic Insights Center in the US as the state is very progressive, has the most cities that decriminalized psilocybin in the country and has the largest population.
Definitive Agreement Terms
- Roadman shall contribute up to $500,000 USD to the partnership in order to launch the center's operations, which the Company will source from financing or selling of assets.
- Roadman Investments and Psychedelic Insights are jointly responsible to manage finances, arranging insurance and deposits, creating a budget, managing expenses and creating financial reports.
- Psychedelic Insights shall contribute to establishing the center's requirements, protocols, patient intakes, promotional marketing, supplier sourcing for needed materials, overall logistical coordination and registration.
- Psychedelic Insights is responsible for a high-quality business plan at least 5 months prior to the launch of the clinic
- Psychedelic Insights is responsible for the coordination and hiring of mental health professionals to operate the center.
RMANF signs definitive agreement with Psychedelic Insights https://www.google.com/amp/s/www.marketscreener.com/amp/ROADMAN-INVESTMENTS-CORP-56930926/news/Roadman-Investments-Signs-Definitive-Agreement-with-Psychedelic-Insights-Solidifying-Psychedelics-30281582/
Shroom Stocks are Getting a Ton of Attention Now. It's not a question of if; it's a question of When RMANF takes OFF!
RMANF: We're in good shape here; we have a major stake C$150,000.00 strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”).
Champignon is a private, research-driven company specializing in the formulation and end distribution of a suite of premium artisanal mushroom health supplements, with the objective of promoting holistic health and wellness. Champignon is equipped with proprietary formulations for three flagship mushroom-extract-infused tea blends and is in the process of conducting extensive taste and product quality tests.
Champion Brands stock went live on March 2nd!
https://champignonbrands.com/
RMANF Holding Up Nicely; She's gonna run Hard and FAST!
Definitive agreement to acquire CLOV :
https://apple.news/AA_1FvAbFRTeZRQfAV4mUzA
Roadman gaining interest
Coiling up
Accumulation
Roadman Investments Completes LOI with Legal Dutch Psilocybin Therapy Center
Thu February 6, 2020 8:00 AM|TheNewswire.ca|About: RMANF
(via TheNewswire)
https://tnw-c.thenewswire.com/data/tnw/clients/logos/1AdyF6Grz.png
VANCOUVER, British Columbia - TheNewswire -February 6, 2020 - Roadman Investments Corp. (RMANF) (TSXV:LITT)(FWB:1QD) ("Roadman Investments" or the "Company") is pleased to announce the completion of a letter of intent for a transaction with Psychedelic Insights Inc. This transaction will create a joint venture for the state of California and will upon psilocybin legalization and or medical approval allow Roadman Investments to open the first psilocybin therapy center in the United States.
Psychedelic Insights is one of the few organizations in the world that offers legal retreats that utilize psychotropic substances (i.e. psilocybin truffles). The company is based in Amsterdam and has a team that consists of experienced professionals utilizing the best practises used in modern science and therapeutic modalities. The company's treatments aim to generate lasting improvements in well-being through moderate-to high doses of psilocybin truffles and a carefully developed treatment process.
Psychedelic Insights meets all government regulations and has an experienced team that performs comprehensive medical screenings to ensure client safety and has professional supervision at every single retreat. Truffles in the Netherlands are considered food and the production, preparation or trading of Truffles falls under the Dutch Commodities Act (Warenwet (WW)). The WW provides general rules on public health, product safety, fair trading and adequate information.
Roadman Investments is anticipating that the model and expertise from clinics in the Netherlands can be transferable to other jurisdictions as medical and legal access to psychedelics continues to open up in the coming years. As psychedelic medicines become more normalized and their use grows Psychedelic Insights' proven results and established protocols will be transferred to the joint venture in the state of California. In June of 2019 Oakland's City Council voted unanimously to decriminalize magic mushrooms and the city of Santa Cruz followed suit and officially decriminalized the substance in February 2020. These legislative changes are signaling the first significant steps toward a much wider mainstream acceptance of psychedelic-assisted therapy in America.
Roadman Investments advisor Dr. Randy Scharlach is based in Los Angeles, California and will be leading the company's efforts for this initiative. Randy is one of few medical doctors in the United States that has completed academic certification in clinical use and research using Schedule 1 psychedelic medicines, is a board member of two respective Los Angeles based Neuroscience institutes and is certified by the Center for Psychedelic Therapy and Research at the California Institute of Integral Studies.
The joint Venture Structure of the operation is as follows:
- 3-year joint venture partnership agreement for the state of California
- Agreed upon financial investment numbers on non-operating, operating and capex costs
- Mutual extension, material adverse changes, termination, and renewal clauses
- Roadman provides all the capital for 51% ownership of the JV
- Dr. Randy Scharlach leads the implementation and local operations for 9% ownership of the JV
- Psychedelic Insights provides the treatment protocols, knowhow and operates that business for 40% ownership of the JV
CEO and Director Luke Montaine stated: "We are truly excited to complete this first step towards establishing a psilocybin therapy center in California. The experienced team at Psychedelic Insights and the leadership from Dr. Scharlach will provide our company a significant competitive advantage and the ability to be first movers once psilocybin is re-scheduled."
Roadman Investments Signs Letter of Intent with CLOV Biopharma Corp.
February 12, 2020-TheNewswire -Vancouver, British Columbia - Roadman Investments Corp. (RMANF) (TSXV:LITT) (FWB:1QD) (OTC:RMANF) ("Roadman Investments" or the "Company") is pleased to announce that it has signed a letter of intent with CLOV Biopharma Corp. ("CBP") pursuant to which Roadman intends to acquire all of the issued and outstanding common shares of CBP.
The mission of CLOV Biopharma Corp. is to conduct further research and development of cedar leaf oil vapour ("CLOV") for the purposes of preventing the spread of Coronavirus and other similar potentially pathogenic respiratory viruses, for example, influenza and para-influenza viruses, and respiratory syncytial virus. CBP intends to manufacture or source a diffuser that is functional with cedar oil that may be effective in killing viruses to prevent them from spreading. CBP has an exclusive license for the right to acquire and use cedar leaf oil vapour, including certain know-how, industry knowledge, and experience relating to CLOV for the pharmaceutical, healthcare, and biotechnology industries.
Previous studies by Dr. James Hudson, Ph.D have shown that most of the human respiratory viruses tested so far have been found vulnerable to cedar leaf oil and cedar leaf oil vapour. It is expected that corona viruses will be similarly vulnerable. In general, the respiratory viruses not only can kill susceptible cells and multiply and spread, but they can also induce the production of excessive amounts of inflammatory cytokines, which can result in chronic inflammation of the lungs, as in bronchitis. Previous tests have shown that cedar leaf oil can inhibit this process in a model cell culture system.
Coronavirus
Coronaviruses (CoV) are a large family of viruses that cause respiratory illness ranging from the common cold to more severe diseases such asMiddle East Respiratory Syndrome (MERS-CoV)andSevere Acute Respiratory Syndrome (SARS-CoV). These two viruses were responsible for pandemics.A novel coronavirus (nCoV), recently formally named "COVID-19" by the World Health Organization,is a new strain that has not been previously identified in humans1.
Coronaviruses are zoonotic, meaning they are transmitted between animals and people. Detailed investigations found that SARS-CoV was transmitted from civet cats to humans and MERS-CoV from dromedary camels to humans. Other known coronaviruses are circulating in animals that have not yet infected humans.
Dr. James Hudson
Dr. James B. Hudson, Ph.D, Professor Emeritus Department of Pathology & Laboratory Medicine at the University of British Columbia, has completed various publications including "The activity of cedar leaf oil vapor against respiratory viruses" in the Journal of Applied Pharmaceutical Science and "The antimicrobial properties of cedar leaf (Thuja plicata) oil" in the International Journal of Respiratory Public Health. Dr. Hudson will assist CBP with further studies to research the effectiveness of CLOV on the Coronavirus.
Dr. Hudson is considered to be one of the foremost virologists in Canada. His qualifications include a BSc (chemistry/physiology), an MSc (biochemistry), a PhD (molecular biology) a post-doctoral fellowship in molecular virology. In addition, he has received visiting professorships in University of Warwick (UK), 1976-1977, and University of Western Australia (Perth WA) in 1990 and 1992.
Of relevance to Coronavirus, Dr. Hudson conducted a study involving seven (7) respiratory viruses that were tested for infectivity following exposure of dried virus films to certified cedar leaf oil vapor for various periods of time. All were susceptible, although the membrane containing viruses, like CoV, were more vulnerable and were readily killed by short exposures without detrimental effects against the human cells.
Luke Montaine, CEO of Roadman Investments commented, "With the death toll from COVID-19 now surpassing that of the SARS epidemic and having forced approximately 50 million human beings currently into quarantine, the global economic and social impact of this virus is of significant concern. Our aim to expand upon the previous scientific research of Dr. James Hudson in an effort to further validate and, if warranted, potentially commercialize a product that may assist in combating the spread of this and other pathogenic viruses."
Under the terms of the letter of intent,Roadman intends to acquire all of the issued and outstanding common shares of CBP in exchange for 13,000,000 common shares of the Company. Further details regarding the proposed transaction with CBP will be provided in a comprehensive news release, if and when, the parties enter into a definitive agreement.
Roadman Investments Investee Champignon Brands Announces Major European Distribution Agreement
VANCOUVER, British Columbia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Roadman Investments Corp. (TSXV: LITT) (FWB: 1QD) (OTC: RMANF) (“Roadman Investments” or the “Company”) is pleased to announce a major distribution partnership between investee Champignon Brands Inc. and Eurolife Brands Inc. (CSE: EURO). Under the terms of the agreement, Eurolife Brands Inc. has been granted exclusive preferred distributor status for the jurisdictions of Germany, Switzerland and the United Kingdom in addition to non-exclusive distribution rights in various other locales globally. Eurolife Brands will integrate Champignon Brands products into its e-commerce platform along with potential distribution in select brick-and-mortar retail locations. Eurolife anticipates placing an initial product purchase order in Q4 of 2019 in order to stock inventory to fulfill initial consumer demand.
"The addition of Champignon products to our suite of health and wellness-oriented CPG offerings is a natural fit," stated Shawn Moniz, chief executive Officer and director of Eurolife. "Informed, educated and health-conscious European consumers demand products that are not only high quality but are on the cutting edge of their respective industry segments and we believe that Champignon fits this criteria.”
The global functional mushrooms market is expected to gain momentum from growing awareness regarding the health benefits of mushrooms and is projected to grow to $34.3 billion by 2024, with Europe experiencing the fastest growth world-wide. *
The Champignon team has been focused on obtaining additional distributor partnerships and has signed up distribution partners in British Columbia, Alberta and Ontario. The company aims to enhance the health and wellness of millions of consumers through organic growing practices, commercial cultivation, research and development, and the distribution of a premium, mushroom-infused suite of products. Champignon is currently working toward a Q4 2019 initial public offering in Canada and is launching several new marketing campaigns to increase online sales of their products.
CEO and Director Luke Montaine commented: “We are thrilled with the progress Champignon is making and this new partnership and foray into the European marketing is a very positive development.”
https://www.globenewswire.com/news-release/2019/11/05/1941094/0/en/Roadman-Investments-Investee-Champignon-Brands-Announces-Major-European-Distribution-Agreement.html
Hello Peeps I'm new here and curious about the Shroom Boom I've heard is coming. I'd appreciate it if anyone can provide some additional DD on RMANF and this sector.
Thx!
Got my eye on this I think there may be one other out there
I guess this is my intro to Shroomstocks! The "sector" has been on my radar for about a year now and I'm finally starting to look into it. I'll be posting whatever I find.
https://www.reddit.com/r/shroomstocks/ is a great place to begin as well!
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
91
|
Created
|
08/22/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |